Lilly recruits Avidity Biosciences to develop antibody-oligonucleotide conjugates

Avidity's technology will help the duo get RNA therapies to immune cells

Source: Chemical and Engineering News - April 22, 2019 Category: Chemistry Authors: Ryan Cross  Source Type: research